Treatment of T2DM Patients in Germany receiving Empagliflozin: A retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany receiving Empagliflozin: A retrospective Real-World Evidence (RWE) study based on German registries DPV&DIVE

Study identification

• EU PAS number:
  EUPAS1000001187
• Study ID:
  1000001187
• Official title and acronym:
  Treatment of T2DM Patients in Germany receiving Empagliflozin: A retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany receiving Empagliflozin: A retrospective Real-World Evidence (RWE) study based on German registries DPV&DIVE
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual:23/07/2019

Study start date

Actual:16/09/2019

Data analysis start date

Actual:01/03/2014

Date of final study report

Actual:31/12/2019

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1245-0198
NCT04098575